source
- Roche's daily incretin injection shows promise in Phase 2 trial for type 1 diabetesRoche reported that its experimental daily incretin injection achieved positive results in a Phase 2 study involving patients with type 1 diabetes. The study, the first mid-stage trial of a GLP-1…
- Supreme Court rules generic Vascepa copy does not infringe patents, boosting skinny-label pathwayThe U.S. Supreme Court issued a decision that Hikma Pharmaceuticals’ generic version of Amarin’s heart drug Vascepa does not infringe the brand’s patents. The ruling clarified that the generic make…